Core Viewpoint - Zhejiang Runyang New Materials Technology Co., Ltd. plans to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., Ltd. to expand its business and enhance its industry layout while maintaining stable development of its main business [1] Group 1: Company Overview - Runyang Technology specializes in the research, production, and sales of irradiated cross-linked polyethylene series products, with its core products including electronic irradiated polyethylene (IXPE) and GFOAM series, ranking among the top in national production capacity [1] - Fourier, established in 2015, focuses on the research and application of intelligent robotics technology, starting with rehabilitation robots and offering over 30 devices, including ExoMotus and ArmMotus series, widely used in various rehabilitation fields [1] Group 2: Investment Details - The investment agreement involves Runyang Technology subscribing to the new registered capital of Fourier, with Fourier's pre-investment overall valuation set at 8 billion yuan [1] - The cash investment by Runyang Technology will not exceed 300 million yuan, indicating a strategic move to diversify and strengthen its business portfolio [1]

Core Viewpoint - Fourier, a humanoid robot company based in Shanghai, has achieved a pre-investment valuation of 8 billion RMB, becoming a "unicorn" [1] Group 1: Investment and Corporate Strategy - Runyang Technology plans to invest up to 300 million RMB in Fourier, with an investment intention agreement already signed [1] - The investment aims to meet the strategic development needs of Runyang Technology, expand its business scope, and enhance its overall competitiveness while maintaining stable growth in its core business [1] Group 2: Company Background and Shareholding Structure - Fourier was founded in July 2015 and recently completed an E-round financing of nearly 800 million RMB on January 7, 2023, with participation from various investment institutions [1] - The founder and CEO, Gu Jie, is the largest shareholder, holding 11.556% of the shares directly, with additional indirect holdings through various partnerships [2][3] Group 3: Product Development and Market Focus - Fourier has released two models of the GR series humanoid robots and is focusing on the rehabilitation scene as the next phase of its embodied intelligence business [1][4] - The company has entered over 3,000 hospitals globally with its rehabilitation robots, emphasizing the importance of interaction between patients and machines [4] Group 4: Challenges in the Medical Field - The implementation of embodied intelligence technology in healthcare is more challenging than in other sectors due to a lack of interdisciplinary talent and high policy barriers [6] - Medical institutions are currently cautious about adopting embodied intelligence robots, preferring to wait for proven efficacy and compliance with national standards [7]

人形机器人公司傅利叶5月9日宣布，把康养作为布局具身智能的场景锚点。 对于这家靠外骨骼康复机器人起家的公司而言，聚焦康养并不意外。但在业内人士看来，人形机器人康 复设备能否真正落地，面临技术研发和医疗监管双重考验。 康养场景"有资源和渠道" 作为从外骨骼机器人赛道切入具身智能的公司，傅利叶先后于2023年和2024年发布两款GR系列的人形 机器人。成立10周年之际，傅利叶把康养场景作为下一阶段具身智能业务的推进方向。 傅利叶发布的两款GR系列的人形机器人。图：杨柳 傅利叶创始人兼CEO顾捷对此解释称，公司从康复机器人起家，和专业医疗团队和患者一起打磨产品。 病人和机器之间的交互，对傅利叶而言是最擅长、最有实战经验的环节，"我们会选择与自身技术和基 础相匹配的场景落地"。顾捷提供的数据显示，傅利叶的康复机器人已进入全球3000多家终端医院。 张毅希望具身智能能为康养服务提供专业化、标准化、精准化的科学方案，并加以规范化操作执行，解 决专业人员水平差距问题。 顾捷提到，不同经验的人类治疗师，其治疗方法和效果可能不同，但机器人可以在质量控制、训练强度 和训练内容等方面实现标准化。治疗师只需调节一些参数，便能适配不同 ...